HER-2 overexpression and activated excessive signaling triggered by pathways including phosphoinositide 3 kinase/Akt/mammalian target of rapamycin (Akt/PI3K/mTOR) may lead to more malignant clinical behaviors, including lymph node metastasis, local invasion, and high recurrence rate (21, 22). The gene discussed is ERBB2; the disease is metastatic malignant neoplasm in the lymph nodes.